Advanced Breast Cancer Therapies

Metabolic-epigenetic coupling between leucine catabolism and glycolysis drives CDK4/6 inhibitor resistance

This study identifies a metabolic-epigenetic mechanism linking leucine catabolism to glycolysis that drives resistance to CDK4/6 inhibitors in ER+ breast cancer.

ERK5 inhibition triggers CDK6 proteasomal degradation and enhances palbociclib efficacy in cancer cells

This study shows that inhibiting ERK5 causes CDK6 degradation and enhances palbociclib's effectiveness in melanoma and endometrial cancer cells.

Risk-Window Palbociclib Exposure Delays ErbB2-Driven Mammary Tumorigenesis and Suppresses Mammary Epithelial Cell Stemness

Short-term palbociclib exposure during a premalignant risk window delays ErbB2-driven mammary tumorigenesis by suppressing stemness and proliferation.

GPNMB overexpression- a marker of resistance to CDK4/6 inhibitors

This study identifies GPNMB overexpression as a marker of resistance to CDK4/6 inhibitors in estrogen receptor-positive breast cancer.

Therapeutic benefits of maintaining CDK4/6 inhibitors and incorporating CDK2 inhibitors beyond progression in breast cancer

This study shows that continuing CDK4/6 inhibitors and adding CDK2 inhibitors slows growth of drug-resistant breast cancer by delaying cell cycle progression and reducing E2F transcription.

WEE1 inhibition delays resistance to CDK4/6 inhibitor and antiestrogen treatment in estrogen receptor-positive breast cancer

This study shows that alternating WEE1 inhibition with CDK4/6 inhibitor and antiestrogen treatment delays resistance in ER+ breast cancer cells.

The non-kinase function of CDK6 is a key driver of acquired resistance to CDK4/6 inhibitors in Estrogen Receptor-positive breast cancer

This study shows that CDK6's non-kinase function drives resistance to CDK4/6 inhibitors in ER+ breast cancer, challenging the assumption that kinase inhibition is the main therapeutic target.

Charting the Multi-level Molecular Response to Palbociclib in ER-Positive Breast Cancer

This study identifies multi-level molecular changes in ER-positive breast cancer cells treated with palbociclib, revealing feedback loops and alternative splicing that suggest new therapeutic strategies.

Pharmacological CDK4/6 inhibitors promote senescence-associated lysosomal alterations and enhance sensitivity to lysosomotropic agents in breast cancer

This study shows CDK4/6 inhibitors induce senescence-like changes in breast cancer cells, increasing their sensitivity to lysosomotropic agents, and suggests sequential treatment could improve therapy efficacy.

JNK pathway suppression drives resistance to combination endocrine therapy and CDK4/6 inhibition in ER+ breast cancer

This study identifies JNK pathway suppression as a driver of resistance to combination endocrine therapy and CDK4/6 inhibition in ER+ breast cancer, with implications for patient stratification.

Exploiting collateral sensitivity controls growth of mixed culture of sensitive and resistant cells and decreases selection for resistant cells

The paper shows that combining ribociclib and adavosertib reduces growth of mixed cancer cell cultures and limits resistance development.